Pharmacy Cancer Clinical Trial Feasibility Checklist Template

**Verison 1**

**Approved: 06/12/2024 by NCCP Cancer Clinical Trials Pharmacist Subgroup**

* **This checklist in not intended to be used with Advanced Therapy Medicinal Products (ATMPs).**
* **To note, this template is intended to be a guide only; the fields included in this form are not mandatory or exhaustive. Some fields will not be relevant to all cancer clinical trials.**
* **This checklist may be adapted for use at each site as deemed applicable to local practice.**

|  |
| --- |
| **General Information** |
| Study Protocol Name: | ABC |
| Protocol Number: | 123 |
| Description:  |  |
| Principal Investigator: |  |
| Investigational Medicinal Product (IMP):  |  |
| Standard Of Care (SOC):  |  |
| Site Number: |  |
| Likely Site Initiation Visit (SIV) Date:  |  |
| Study Type: | **[ ]** Open -label[ ] Blinded [ ]  (All staff are blinded)**[ ]  (**Pharmacy staff are unblinded) |
| Research nurse: |  |

|  |
| --- |
| **Clinical Trial Impact Assessment** |
| Recruitment period |  |
| Target patient number for this site |  |
| Oral agents only in trial? | **[ ]** Yes **[ ]** No  |
| Aseptic Compounding required?To note, the complexity band definitions outlined in Appendix 2 of the NCCP Parenteral SACT Capacity Planning Toolkit User Manual may be useful – linked [here](https://www.hse.ie/eng/services/list/5/cancer/profinfo/medonc/sactguidance/aseptic%20unit%20capacity%20planning%20user%20manual.pdf) | **[ ]** Yes **[ ]** NoCompounding complexity / time to compound:  |
| Special storage requirements, e.g. freezer |  |
| Frequency of dispensing episodes  |  |
| Frequency of monitoring visits | **[ ]** In person [ ] Remote |
| Specific non-routine testing (e.g. molecular) required? |  |
| Is Pharmacy specific training required (post SIV)? | **[ ]** Yes [ ] No |
| Are any specific biosimilar (s) / brand of drug required for use in the trial? | **[ ]** Yes [ ] No**[ ]** Details \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| If CSTD in use at site  | [ ] CRA informed of local practice  |

|  |
| --- |
| **Impact on Pharmacy Services** Questions to consider in addition to the information above:  |
| How does this study differ from the normal clinical pathway? |  |
| How many patients on this trial can pharmacy reasonably accommodate per week considering current ACU/ dispensary capacity? |  |

|  |
| --- |
| **Other relevant notes (Practical aspects) / Items which require follow up** |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|   |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |